- Pretty soon they'll be putting it in the water. A couple pieces in the UK Guardian over the weekend about the potential fluoridization of statins in the UK. Followed up this morning, here, is the plan's downside.
- GPC Biotech continues to deal with the wake of its satraplatin review. Late Friday night the company reported the first class-action lawsuit it will face. And over the weekend Reuters reported that GPC's largest investor, SAP co-founder Dietmar Hopp, increased is stake in the company to more than 14% as its shares have slipped.
- A new use for those old pills. The AP reports on drug-disposal companies that can turn pharmaceuticals into energy.
- Finally, a big day for Avandia today ... more to come on the IN VIVO Blog.
Monday, July 30, 2007
While You Were in Springfield
D'oh! It's back to the daily grind. IN VIVO Blog picked up on a few stories you may have missed over the lazy summer weekend.